Biotech Archives - Page 767 of 795

1 minute read

Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation

July 26, 7:37 AM

Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)

DFFN

2 minute read

Unicycive Reports Findings from Independent Renal Dietitian Survey

By Bill Haddad

July 26, 7:10 AM

Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are swallowed vs

UNCY

2 minute read

Bausch + Lomb Enrolls First Patient In LASIK Clinical Trial Evaluating Use Of Technolas TENEO™ Excimer Laser For Vision Correction Surgery for Hyperopia with Astigmatism

By Benzinga Newsdesk

July 26, 6:59 AM

Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that the company has enrolled the first patient

BLCO

1 minute read

FDA
News

Immuron Announced US DoD Naval Medical Research Center Received feedback on IND Application for New Campylobacter ETEC Therapeutic; Said IND Does Not Contain Sufficient Information

By Charles Gross

July 26, 5:45 AM

:Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the US Naval Medical Research Center (NMRC) has received feedback from the US Food and Drug Administration following a review of the Investigational New Drug (IND) applica

IMRN

1 minute read

This Small Cap Cancer Company ‘Hijacks Tumors From Within,” HC Wainwright Says

By Vandana Singh

July 25, 2:22 PM

HC Wainwright has initiated coverage on Genenta Science SpA (NASDAQ:GNTA) with a Buy rating and a price target of $25. “We like Genenta’s…

GNTA

1 minute read

Regeneron’s Price Target Cut On Dim Prospects For Its Flagship Eye Product

By Vandana Singh

July 25, 12:25 PM

SVB has cut the price target from $738 to $630 and downgraded from Outperform to Market Perform to reflect Regeneron Pharmaceutical Inc’s (NASDAQ:REGN)…

REGN

1 minute read

Vaxxinity CEO Mei Mei Hu Speaking At White House Summit On Future of COVID-19 Vaccines

By Benzinga Newsdesk

July 25, 11:58 AM

Vaxxinity, Inc. (NASDAQ:VAXX) Chief Executive Officer Mei Mei Hu will participate as a speaker at the White House Summit on the Future of COVID-19 Vaccines. Hu is honored by the invitation and eager to engage in

VAXX

1 minute read

HOOKIPA Gets FDA Nod For Initial-Stage Prostate Cancer Study

By Ragothaman Srinivasan

July 25, 11:49 AM

The U.S. Food and Drug Administration (FDA) has accepted HOOKIPA Pharma’s (NASDAQ: HOOK) Investigational New Drug (IND) application for HB-300, a novel arenaviral immunotherapy for the treatment of metastatic castration-resistant prostate cancer.

HOOK

1 minute read

FDA Accepts AstraZeneca’s Submission For Low Breast Cancer Candidate Under Priority Review

By Ragothaman Srinivasan

July 25, 10:21 AM

The United States Food and Drug Administration (FDA) has accepted to review the supplemental Biologics License Application (sBLA) of AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo’s lead asset ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable

AZN

4 minute read

FDA
News

Athenex Announces Publication Of Data From Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel In Patients With Metastatic Breast Cancer In The Journal Of Clinical Oncology

By Benzinga Newsdesk

July 25, 10:02 AM

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology BUFFALO,

ATNX